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Abstract 
Cancer poses a tremendous therapeutic challenge worldwide, highlighting the critical need for 
developing novel therapeutics. A promising cancer treatment modality is gene therapy, which is a 
form of molecular medicine designed to introduce into target cells genetic material with therapeutic 
intent. Anticancer gene therapy strategies currently used in preclinical models, and in some cases in 
the clinic, include proapoptotic genes, oncolytic/replicative vectors, conditional cytotoxic 
approaches, inhibition of angiogenesis, inhibition of growth factor signaling, inactivation of 
oncogenes, inhibition of tumor invasion and stimulation of the immune system. The translation of 
these novel therapeutic modalities from the preclinical setting to the clinic has been driven by 
encouraging preclinical efficacy data and advances in gene delivery technologies. One area of intense 
research involves the ability to accurately regulate the levels of therapeutic gene expression to achieve 
enhanced efficacy and provide the capability to switch gene expression off completely if adverse 
side effects should arise. This feature could also be implemented to switch gene expression off when 
a successful therapeutic outcome ensues. Here, we will review recent developments related to the 
engineering of transcriptional switches within gene delivery systems, which could be implemented 
in clinical gene therapy applications directed at the treatment of cancer. 
Introduction 
In the United States alone, cancer accounts for ~ 23% of all deaths yearly, ranking only second 
to heart disease (1). This highlights the critical need for the development of novel therapeutic 
approaches to reduce the public burden of cancer. One promising cancer treatment modality 
is gene therapy, which is a form of molecular medicine designed to introduce into target cells 
genetic material with therapeutic intent. Worldwide, nearly 1,000 gene therapy clinical trials 
have been or are being conducted, and of these, two thirds are for treating cancer (2); in 2004, 
the first gene therapeutic product consisting of a replication-deficient adenovirus encoding p53 
(Ad-p53; Gendicine) was approved for commercial use by China’s State Food and Drug 
Administration for head and neck squamous cell carcinoma. Some of the best outcomes have 
been observed when Gendicine has been used in combination with conventional treatments, 
that is, radiation to treat nasopharyngeal cancer (3), or with transcatheter hepatic arterial 
chemoembolization to treat hepatocellular carcinoma. Recently, the first oncolytic adenoviral 
vector, H101, was approved by the State Food and Drug Administration as a commercial gene 
therapeutic product (4), which is used in combination with local heat treatment and 
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chemotherapy for late-stage refractory head and neck cancers.1 Interestingly, although gene 
therapy remains, in the western markets, a promising therapeutic approach, in China it is 
currently being implemented in the clinic. The only two companies with commercial gene 
therapy products are Chinese. Their gene therapy vectors have been in the market for several 
years without reported deleterious side effects. The reasons why the first commercial gene 
therapy treatment got produced and approved in China could be due to the fact that the prospect 
of a one-time treatment, simple to administer is very compelling; also, due to the large 
population in China, it is possible to recruit enough patients for a clinical trial in a short 
timeframe and generate statistically significant clinical data in a timely fashion. Importantly, 
China has not been affected by adverse events, as in the United States, with the death of Jesse 
Gelsinger of a serious adverse event due to gene therapy for an inherited metabolic disorder 
(5) and more recently in Europe with adverse events reported in the X-linked, severe combined 
immunodeficiency syndrome trials (6). Finally, the Chinese regulatory authorities may be more 
receptive to this technology. The translation of these novel treatment modalities from the 
preclinical setting to the clinic has been driven by encouraging efficacy data and advances in 
gene delivery technologies. One area of intense research involves the ability to accurately 
regulate the levels of therapeutic gene expression to achieve enhanced efficacy and provide 
the capability to switch gene expression off completely if adverse side effects should arise. 
Here, we will review some of the recent developments related to the engineering of 
transcriptional switches within gene delivery systems, which could be implemented in clinical 
gene therapy applications. 
Regulating Gene Expression for Cancer Therapy 
For gene therapy to become a successful and widely used clinical modality, it will be critical 
to regulate the expression of the therapeutic transgenes according to clinical needs and also to 
curtail any putative adverse side effects of the therapy. A promoter that is sensitive to changes 
in the environment of cells/tissues is the basis for achieving regulatable therapeutic gene 
expression. Inducible gene transfer vectors encode promoters that are regulated by transcription 
factors sensitive to physiologic changes (heat shock, metal ions, IFNs, and dsRNA) or 
exogenous chemicals (rapamycin and steroids; Table 1; ref. 7). Coexpression of both the 
regulated transcription factor and the inducible promoter within the same vector improves 
specificity of gene expression and allows using a greater range of promoters, even those that 
are not normally expressed in the target cell, such as a mutated steroid receptor with high 
affinity for the antagonist mifepristone, the tetracycline-dependent system (Tet system) and 
the insect steroid hormone ecdystone receptor system (Table 1;ref. 7). The Tet system has 
several advantages, given that tetracycline and its analogues have been proven to be nontoxic 
in human patients, the promoter has negligible leakiness in the “off” state (8,9), has rapid 
induction and repression kinetics in vivo (9), and is not expressed normally in mammalian cells, 
which gives it higher specificity over steroid receptor-based systems. Also, the small size of 
the expression cassette of the Tet system (~ 3 kB) allows it to be encoded within most viral 
vectors (7). The potential disadvantage of using prokaryotic transcriptional systems is that they 
might be immunogenic in mammalians. However, we have shown that the components of the 
Tet-On regulatable system are weakly immunogenic, and pre-exposure to the proteins encoded, 
that is, rtTA2S-M2 and tTSKid, do not significantly affect transgene expression in the central 
nervous system from Tet-regulated adenoviral vectors in preclinical models (10). Considering 
that the Tet-On system is the most widely used regulatable system in preclinical cancer 
research, and other regulatable systems have been reviewed in detail elsewhere (7), we will 
focus on the Tet-On regulatable system throughout this review, although many of the principles 
discussed can also be applied to other regulatable systems. Please see Table 1 for a summary 
1http://www.oralcancerfoundation.org/news/story.asp?newsId=1033 
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description of other commonly used regulatable systems, including advantages and 
disadvantages for each one. 
Tet System through the Ages: Progress Made Since the 1980s 
The first Tet system was described in Escherichia coli, where the Tet repressor protein inhibits 
the transcription of genes in the tetracycline resistance operon on the Tn10 transposon by 
docking to the Tet operator sequences in the absence of tetracycline (11). The engineering of 
the Tet repressor protein over the following 20 years led to several systems with improved 
inducibility, stringent regulation of transgene expression, and negligible leakage. The first- 
generation Tet system, i.e., the Tet-Off switch, drive transgene expression in the absence but 
not in the presence of tetracycline. In this system, the Tet repressor protein was fused to a viral 
protein domain VP16, a eukaryotic transactivator derived from HSV-1, converting the Tet 
repressor protein from a repressor to a transactivator (tTA). The tTA is constantly expressed 
under the control of a constitutive promoter but induces the activity of the TRE promoter only 
in the absence of tetracycline. The TRE promoter is composed of seven recurring Tet operator 
sequences and the minimal human cytomegalovirus promoter, which ultimately drives 
therapeutic transgene expression. The TRE promoter activity is triggered when the 
transactivator tTA binds to Tet operator in the absence of tetracycline, inducing therapeutic 
transgene expression. Tetracycline and its analogues bind to the tTA and hinder the capacity 
of the tTA to become docked to the Tet operator sequences within the TRE, inhibiting the 
transcriptional activity of the promoter. Thus, addition of tetracycline results in inhibition of 
therapeutic transgene expression. The Tet-Off switch has been encoded within an adenoviral 
vector expressing the proapoptotic protein Bax to induce apoptosis of human lung cancer cells; 
its effects can be blocked by addition of tetracycline (12). Regulated delivery of tyrosine 
hydroxylase was implemented in preclinical models of pituitary adenomas using adenoviral 
vectors encoding the Tet-Off system (13). Although tyrosine hydroxylase expression leads to 
successful regression of pituitary hyperplasia and normalization of serum prolactin levels, 
chronic overexpression of tyrosine hydroxylase could elicit pituitary insufficiency. This 
adverse effect could be reverted by switching off tyrosine hydroxylase expression. Although 
the Tet-Off system has been criticized because it exhibits 1% to 10% leakage in the “off” state 
(12), it still allows to substantially reduce transgene expression when side effects arise. For 
instance, the severe side effects associated to the systemic administration of interleukins (IL) 
for the treatment of colon cancer led to the construction of adenoviral vectors expressing IL-12 
driven by the Tet-Off system, which yields high levels of IL-12 that are inhibited 99% in the 
presence of doxycycline (14). Retroviruses encoding the Tet-Off system also produce high 
levels of thymidine kinase, with <0.5% basal expression in the “off” state (15). A potential 
pitfall of the Tet-Off system is that inhibition of transgene expression after regression of the 
tumor requires chronic administration of tetracycline. 
Mutations to the tTA led to a novel transactivator, rtTA, which binds the TRE promoter in the 
presence of tetracycline. This system, that is, Tet-On, has the advantage of driving therapeutic 
transgene expression only in the presence of the inducer, remaining inactive in its absence. 
However, the rtTA transactivator has residual affinity for the TRE in the absence of the inducer, 
exhibiting some degree of basal transgene expression (16–18). This drawback was overcome 
by engineering the rtTA and the TRE promoter, leading to negligible background expression 
in the absence of the inducer (19–21). Further mutagenesis of the rtTA generated a mutant 
transactivator, rtTA2S-M2, which yields higher levels of transgene expression in the presence 
of the inducer and virtually negligible basal expression in its absence (19). To this end, 
regulation of oncolytic adenoviral replication in lung cancer cells was achieved by expressing 
the E1 gene, essential for adenovirus replication, under the control of the TRE promoter (22). 
Cell type specificity of replication was accomplished by encoding the transactivator rtTA2S- 
M2 under the control of a lung cancer cell promoter. Engineering of the TRE promoter reduced 
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10-fold the basal expression from adenoviral vectors encoding the highly cytotoxic FasL under 
the control of the Tet-On system, leading to stringent regulation of cell death in lung cancer 
cells (23). To further reduce the already very low basal levels of expression from the second- 
generation Tet-On system, encoding the novel rtTA2S-M2 transactivator, a transrepressor 
(tTSKid) was developed that binds and represses the TRE promoter in the absence but not in 
the presence of tetracycline (24). Addition of the inducer, in turn, prevents binding of tTSKid 
relieving repression, and promoting binding of transactivator to the TRE promoter, leading to 
nonleaky transgene expression. Another advantage of the transrepressor is that its presence 
inhibits the ubiquitin-dependent proteosomal degradation of the transactivator, leading to 
increased amounts of transactivator available for activation of the TRE when the inducer is 
added, which in turn increases the levels of transgene expression in the “on” state (18,25). 
Table 2 shows that the evolution of the Tet-On system, from the first-generation switches 
encoding the rtTA to the third-generation switches comprising the rtTA2S-M2 and the 
transrepressor tTSKid, resulted not only in enhanced levels of expression in the “on” state but 
also in negligible transgene expression in the “off” state. This third-generation Tet-On switch 
has been shown to be very effective in achieving tight regulation of transgene expression in 
mice, rats, and nonhuman primates (9,17,26). Figure 1 shows the virtual absence of leakage 
from regulated high-capacity adenoviral vectors expressing different transgenes, such as a 
cytoplasmic enzyme (β-galactosidase; Fig. 1A) and a secreted cytokine (Flt3L; Fig. 1B). This 
third-generation Tet-On system also exerts tight regulation and strong induction of transgene 
expression bidirectionally yielding isomolar production of IL-13 and IL-4 when encoded by 
an adenoviral vector expressing these transgenes under the control of the bidirectional TRE 
promoter (Fig. 1C). 
Considering the prokaryotic origin of the Tet-On switch components, rtTA2S-M2 and 
tTSKid, the likelihood of immune responses against these exogenous proteins has to be taken 
into account when using these inducible systems for therapeutic transgene expression. After 
systemic administration of high doses of high-capacity adenoviral vectors (27), immune 
responses against the components of the Tet-On switch are triggered, causing a reduction in 
the longevity of transgene expression. This has been overcome by reducing the dose of the 
vector (27) or by expressing the Tet-On switch under the control of a cell type–specific 
promoter, which inhibits expression of the Tet-On components in professional antigen- 
presenting cells (27). In the brain, however, the systemic immune status against the components 
of the Tet-On switch seems to have less of an effect on the longevity and stability of transgene 
expression from high-capacity adenoviral vectors. Pre-exposure to the Tet-dependent 
regulatory proteins does not severely compromise regulated transgene expression from high- 
capacity adenoviral vectors delivered in the brain, with expression remaining detectable for up 
to 7 weeks postdelivery of the high-capacity adenoviral vector into the brain parenchyma 
(10). Thus, the regulatory switch composed of rtTA2S-M2 and the tTSKid appears as a safe 
and very useful tool for regulating gene expression in the brain. 
In summary, the latest-generation Tet-dependent transcriptional regulatory system that 
comprises the transactivator rtTA2S-M2 and the transrepressor tTSKid exhibits all the features 
of an ideal transcriptional regulatory system: high levels of transgene expression in the induced 
state, negligible transgene expression in the repressed state, quick response to the 
administration or removal of the inducer, and negligible cytotoxic or inflammatory responses 
associated with the regulatory elements within the switch system or with the inducer. Also, the 
possibility of encoding the Tet-dependent transactivators under the control of cell type–specific 
promoters makes this system very versatile to target transgene expression to specific cancer 
cells. The advantages and disadvantages of the Tet regulatable system compared with other 
commonly used regulatable systems are outlined in Table 1. 
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Regulating Gene Expression for Cancer Therapeutics: Seeing the Light at the 
End of the Side Effects Tunnel 
Toxicity 
The toxic dose (determined in phase I trials) and the effective dose (characterized in phase II 
and III trials) of any new drug must be determined during controlled, regulated clinical trials 
in a relatively small number of patients. Any new therapy will have a threshold above which 
toxic effects can be routinely observed. The doses are adjusted to determine therapeutic efficacy 
at doses that do not cause severe (grade 3 or 4) side effects. Increased toxicity usually correlates 
with decreased specificity of the therapeutic anticancer strategies. As an example, we will 
discuss the use in clinical trials of a peptide that inhibits the serine protease urokinase 
plasminogen activator (uPA) receptor activity (A6) tested in patients with gynecologic cancers 
in a phase I trial (31). Expression of uPA receptor or the ligand uPA strongly correlates with 
metastatic disease and it was proposed that uPA and uPA receptor inhibitors would limit tissue 
invasion and metastasis. In this trial, in one patient who received the highest dose of A6 (300 
mg/d by s.c. injection), mild neurologic disorders developed (oropharyngeal hypoesthesia, 
sensory neuropathy, and dizziness). It was also determined that moderate muscle weakness 
and progressive abdominopelvic disease detected on computed tomographic scans that were 
most probably due to A6. These symptoms became evident 3 months after beginning therapy 
and were resolved after stopping the therapy for 2 weeks. When the therapy was restarted, the 
symptoms developed again 1 month later (31). Another example of toxicity was evident when 
depleting antibodies were used to reduce expression of vascular endothelial growth factor 
(VEGF), a potent angiogenic molecule implicated in tumor maintenance and progression. 
Cancer arises after accumulation of mutations in the genome, which predispose daughter cells 
to the acquisition of traits that favor uncontrollable cell proliferation at the expense of other 
cells in the body. These mutations generally occur in a certain order and this genetic pathway 
to cancer has been most fully investigated to date in colon cancer (28). Several genetic 
mutations in p53, ATM, NF-1, P16, and Rb have also been identified that predispose 
individuals to central nervous system cancers, including glioma and other cancers (29). 
Strategies that are currently used to treat cancer in the clinic and in preclinical models usually 
attempt to kill or otherwise incapacitate cancer cells while sparing normal cells. Seven 
hallmarks of cancer have been identified, that is, insensitivity to proapoptotic stimuli, increased 
angiogenesis, deregulation of cell cycle control, activation of growth factor signaling, mutation 
of oncogenes/tumor suppressors, increased tissue invasion, and evasion of the immune system 
(30). By specifically targeting one or several of these pathways, it should theoretically be 
possible eradicate cancer cells from the patient while minimizing adverse toxic events. 
In the clinic, several key issues need to be considered before chemotherapeutic/oncolytic agents 
can be administered to patients with a high degree of safety while retaining their efficacy. These 
include the following: (a) toxicity: relates to uncovering putative adverse side effects arising 
in response to acute or chronic exposure to the drug. (b) Route of administration: local versus 
systemic. (c) Pharmacokinetics and pharmacodynamics: relate to determining the half-life and 
clearance of drugs; establishing the duration and frequency of administration (that is, single 
versus multiple dosage) required to achieve therapeutic benefits without adverse effects. (d) 
Adverse drug reactions: identifying and avoiding unwanted interactions with other therapies. 
To address these issues, novel drug formulation (that is, slow release), changing the frequency 
or route of administration, increasing or lowering the dose, and halting the treatment are all 
strategies that can be employed to enhance efficacy while minimizing adverse events. In the 
following sections, we will discuss how these issues affect the safety and efficacy of anticancer 
therapeutics and how regulatable expression cassettes can be used to optimize gene therapy 
strategies for cancer treatment/management. 
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When antibodies against VEGF that hamper its binding to the VEGF receptor were 
administered i.v. to breast cancer patients, 40% of the patients developed grade 3 hypertension 
and 100% if the patients exhibited hemorrhagic episodes (32), almost certainly related to the 
blocking of endogenous VEGF vasodilator and procoagulant effects. After the administration 
of this treatment to patients with brain tumors, four patients developed grade 4 thromboembolic 
complications resulting in the death of two patients (33). Another example of toxic side effects 
arising from lack of specificity is the implementation of a chimeric toxin composed of IL-13 
fused to Pseudomonas exotoxin (Cintredekin Besudotox hIL13-PE) for the treatment of 
patients with glioblastoma multiforme (34). hIL-13-PE was not designed to treat brain tumors 
but rather to compare its efficacy with an IL-4-based cytotoxin in renal carcinoma (35). 
Nevertheless, a high proportion of human glioblastoma multiformes overexpress a mutant 
IL-13Rα2 receptor, which can be targeted using this chimeric cytotoxin approach (34,36). In 
a phase III clinical trial for glioblastoma multiforme, dose-related neurologic side effects arose 
in most of the patients after the intracranial administration of hIL13-PE (34). IL-13 can also 
bind to the physiologic IL13/IL4 receptor expressed in normal cells. Therefore, the toxic side 
effects encountered with this therapeutic approach could be due to the lack of specificity of 
the targeted ligand (that is, IL13). The targeting of IL-13Rα2 would be greatly improved by 
using the mutated form of IL-13, which has higher specificity for the IL13Rα2 receptor 
expressed on a significant proportion glioblastoma multiforme cells and negligible binding to 
the normal IL13/IL4 receptor expressed in normal brain cells (36). The severity of the side 
effects induced by these drugs underscore how clinical trials are an essential part of testing 
new therapies to identify potential problems in small numbers of patients before testing for 
efficacy in larger cohorts of patients, also highlighting how the ability to regulate the levels of 
the active therapeutic compound could aid in minimizing putative adverse events. 
Route of Administration 
The accumulation of chemotherapeutic drugs in different body compartments, hence the 
toxicity of the drugs, varies depending on the route of administration. Ideally, drugs would be 
delivered locally to the tumor that would limit the toxic side effects associated with the 
treatment regimen. However, local administration of chemotherapeutic agents can be costly, 
inefficient, or inconvenient. Gene therapy vectors can express highly toxic genes from within 
the tumor, that is, locally. One of the advantages of using gene therapy is that the expression 
of the therapeutic genes from within tumor cells might avoid the more serious side effects 
associated with systemic administration. To exemplify the scenario described in the section 
above, adenoviral vectors expressing antisense uPA receptor and uPA inhibited invasion and 
induced regression of human brain tumor xenografts in mice (37). Expression of the serine 
protease inhibitor Maspin (SERPINB5) using adeno-associated virus inhibits prostate cancer 
growth when delivered using adeno-associated virus vectors (38). VEGF receptor signaling 
has been similarly blocked in preclinical gene therapy trials with the adeno-associated virus– 
dependent delivery of soluble VEGF receptors that inhibited angiogenesis and metastasis and 
induced regression of several tumor mouse models with no adverse events (39). However, in 
the clinical scenario, in spite of local delivery of the gene therapy vectors into the tumor mass, 
the potential for the development of adverse events encourages the use of regulatable gene 
expression systems. For instance, local delivery of oncolytic adenoviruses (ONYX-015) in the 
tumor bed after surgical resection in glioblastoma patients showed that the treatment is well 
tolerated in a phase I clinical trial (40) and this virus is already approved for the treatment of 
head and neck cancer in China (4). However, in case of tumor regression, it would be highly 
desirable to inhibit viral replication that could affect normal cells. ONYX-015 has a deletion 
in the E1-B region, allowing replication in p53 null tumor cells, but replication fails to proceed 
in p53-competent normal cells. Addition of regulated and cancer cell-specific promoters to 
replication-competent viruses could further improve the safety of these vectors by reducing 
the chance of replication in normal cells. In fact, regulated replication of oncolytic adenovirus 
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was achieved in lung cancer cells by expressing the E1 gene under the control of the TRE 
promoter (22), whereas cell type specificity of replication was carried out by encoding the 
transactivator under the control of a lung cancer cell promoter. 
Pharmacokinetics and Pharmacodynamics 
The route of administration also greatly determines many of the pharmacokinetic and 
pharmacodynamic properties of a drug. These values must be empirically derived from clinical 
trials and preclinical studies to identify the best route of administration and dose of a new 
therapy. Many of the recombinant proteins that are now being tested in the clinic have very 
short half-lives. A good example of cytokines that have a half-life of <1 h includes soluble 
TRAIL with a half-life in plasma of 32 min (41). Similarly, tumor necrosis factor-α (TNF-α), 
IL-1, IL-2, and IL-6 all have half-lives following i.v. delivery of <15 min. Targeted 
immunotoxins conjugated to cytokines are also rapidly eliminated from the body. The chimeric 
toxin composed of IL13 and Pseudomonas exotoxin (Citredekin Besudotox) has a half-life of 
2 h after intratumoral administration (42); thus, high doses and repeated, prolonged 
administration, typically 4 to 6 days, were required to maintain therapeutic levels of the protein 
into the tumor mass (42). Peptides have very short half-lives because their small size and 
relative hydrophilicity increase the rate of filtration by the kidneys. The uPA receptor inhibitor 
A6 has a half-life of <2 h (31) and uPA inhibitor WX-671 has a half-life of 5.8 h when given 
orally (43). The advantage of using drugs with short half-lives is that they can be rapidly 
removed from the patient should adverse reactions develop. Unfortunately, the therapy must 
usually be administered either at relatively high concentration and/or frequency to maintain an 
effective dose. Generally, altering the route of delivery or the formulation of a new drug can 
increase the half-life of these therapeutic compounds. Formulation of recombinant Flt3L in a 
sustained release Poloxamer-407-based matrix increased the half-life from 5.2 to 11.7 h in mice 
(44) and i.p. delivery increased the half-life of recombinant glycosylated GMCSF to 25 h when 
the half-life was only 3 min when administered i.v. (45). A disadvantage of changing the route 
of administration is that maintaining the effective concentration of the drug at the tumor may 
not be possible. Gene therapy can overcome disadvantages of frequent dosing schedules and 
routes of administration by expressing de novo therapeutic proteins from within the tumor. It 
is usually difficult, however, to adjust the concentration of the therapeutic gene product when 
constitutive promoters are used. Instead, the common practice is to administer a defined number 
of gene delivery vectors/particles to the patient to try to induce gene expression within a 
therapeutic “range.” Regulatable gene expression vectors allow the concentration of a gene 
product to be adjusted, in addition to switching on or off gene expression if adverse effects 
should ensue. This can be achieved by alternating the dosing schedule of the small-molecule 
inducer, thus altering the concentration of the therapeutic gene product to a desired level 
between minimum and maximum expression levels. 
Adverse Drug Reactions 
Perhaps the most difficult toxic effect to predict is the adverse pharmacologic interactions that 
occur between a new therapy and existing therapies. Adverse pharmacologic interactions are 
the most common cause of therapy-induced death in patients, accounting for 160,000 hospital 
deaths each year (46). Flavopiridol, an inhibitor of the cyclin-dependent kinases CDK2 and 
CDK4, was tested in a phase I clinical trial and was shown to be well tolerated in patients 
(47). Flavopiridol was found to be safe in combination with cisplatin, docetaxel, and irinotecan, 
but unexpected severe toxicity was noted when flavopiridol was combined with a DNA 
alkylating agent, carboplatin, resulting in pulmonary embolism and death in one patient (47). 
Regulatable gene therapeutic vectors, either using small molecule–sensitive promoters such as 
the Tet-On system or suicide genes such as thymidine kinase to kill cells expressing the 
therapeutic gene, would be critical to reduce or eliminate the expression of the therapeutic gene 
if adverse reactions are observed. 
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Is Regulation a Must for Gene Therapy Applications? 
Ongoing research is harnessing the immune system as a means to eliminating tumors. These 
immunotherapies are administered to cancer patients either alone or (most often) in 
combination with established therapeutic regimens. As outlined below and reviewed elsewhere 
(48), several promising gene therapy strategies have been developed in preclinical models to 
stimulate adaptive immune responses against tumors. However, tumors share many antigens 
with normal healthy tissue; therefore, a potential drawback with the use of immunotherapy is 
the development of autoimmunity (Fig. 2). Nonregulated immune-mediated gene therapy could 
promote the progression and the severity of the autoimmune response and timely elimination 
of gene expression would be essential to limit any potential long-term damage. Thus, 
regulatable gene expression would be desirable in situations where long-term adverse side 
effects might develop, in response to immunotherapeutic strategies or cytotoxic cytokines that 
can enter the systemic circulation. To promote immune responses against tumor antigens, 
approaches such as administration of cytokines that drive infiltration of immune cells into the 
tumor are being pursued. These strategies elicit the presentation of tumor-derived antigens to 
T cells or the transient depletion of regulatory T lymphocytes to mobilize systemic immune 
responses that specifically target tumor cells (Fig. 2). 
Other gene therapy approaches have exploited the properties of death receptor ligands, such 
as TNF-α, which bind to receptors on tumor cells and induce apoptosis via conserved 
intracellular signaling pathways. TNF-α receptor is expressed on the majority of cells in the 
body, so regulation of TNF-α expression is required to reduce toxicity. A vector called 
TNFerade was developed by Genvec to regulate expression of TNF-α using an early growth 
response 1 promoter activated by ionizing radiation. This leads to high expression of TNF-α 
in the area receiving radiation and allows down-modulating transgene expression if severe 
systemic side effects arise. Importantly, radioinducible promoters allow spatial and temporal 
control of transgene expression for cancer therapeutics. Initial phase I results confirmed that 
regulated TNF-α expression was well tolerated with no dose-limiting toxicities observed 
(49). TNFerade is currently undergoing evaluation in a multi-institution randomized phase II/ 
III trial for patients with locally advanced pancreatic cancer. Genvec have recently announced 
that the median survival was 19.3 months for patients treated with TNFerade in combination 
with standard of care compared with 11.1 months for patients receiving standard of care alone 
(50). 
Regulation of gene expression may not be required for every gene therapeutic target. For 
example, restoration of p53 using adenoviral vectors (INGN 201) has been conducted in phase 
III clinical trials in patients with advanced carcinoma (51) with very limited side effects due 
to p53 overexpression. This is because p53 is expressed intracellularly and is not toxic when 
overexpressed in normal healthy cells. Other oncogenes have been similarly targeted using 
adenoviral vectors addicted to certain transcription factors. Most notable of these is ICOVIR-5, 
an adenovirus that requires the absence of the tumor suppressor gene Rb to drive its life cycle. 
In preclinical models, ICOVIR-5 shows potent antiglioma effects alone and in combination 
with the mTOR kinase inhibitor RAD001 or the alkylating agent temozolomide (52). In these 
situations, local delivery of adenoviral vectors into the tumor is usually sufficient to limit any 
side effects that are determined to be caused by the transgene. Signal transduction from 
oncogenes can also be inhibited in tumor cells using short hairpin RNA or kinase inactive 
mutants. Intratumoral delivery using viral vectors is generally sufficient to limit toxicity 
associated with inhibiting growth factor signaling in normal cells. Some gene therapies, such 
as HSV-1 thymidine kinase, require the administration of a prodrug that is metabolized into a 
toxic product by the enzymatic activity of the gene therapy. Phase II clinical trials using 
adenoviral vectors constitutively expressing HSV-1 thymidine kinase were recently completed 
and a randomized phase III clinical trial has just commenced to treat glioblastoma multiforme 
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(53). Regulatable gene expression would not be necessary when using these conditional 
cytotoxic anticancer approaches because withdrawal of the prodrug will limit therapy- 
associated toxic events. 
The ideal scenario is that regulatable systems will become accessible for use in most gene- 
based anticancer therapeutics as the inherent ability to switch a gene “off” or modulate the 
intensity of expression has advantages over constitutive expression. However, due to 
considerations of the extra time and cost to develop these regulatable switches for gene therapy 
applications, it is likely that in the near future regulatable cassettes will be primarily developed 
to express highly toxic gene products. On a longer timescale, we expect that as regulatable 
cassettes are further developed, more investigators will choose to place the therapeutic gene 
(s) of choice under the control of regulatable promoters to improve the efficacy and safety of 
the therapies. 
Conclusions and Future Prospects 
The ability to tightly regulate therapeutic gene expression for the treatment of cancer is critical 
to achieve greater treatment efficacy and also, very importantly, to minimize any putative 
adverse events. This is an area of very active research both in basic developments of novel, 
more effective, less immunogenic switches and in the preclinical testing to drive expression 
of anticancer target genes in relevant animal models of cancer. In this review, we have discussed 
the advantages of being able to regulate the expression of genes that have the potential of 
providing novel therapeutic targets and improved strategies for the treatment of cancer. The 
fact that several signal transduction pathways, such as growth factor receptor and apoptotic 
signaling pathways, as well as angiogenesis and cell motility, are mostly affected in cancer 
cells provides a unique opportunity for therapeutic intervention. Nevertheless, these signaling 
cascades and growth factor receptors can also be present in normal, noncancerous cells; 
therefore, treatments aimed at these targets can also adversely affect the functioning of normal 
tissues. This poses a critical need to develop and test regulatable expression systems, especially 
in vivo, in appropriate preclinical models, to limit any potential systemic toxicity before we 
can actually embark on translational testing in human clinical trials. Further, these gene 
therapeutic approaches could be used in conjunction with other chemotherapeutic agents to 
overcome drug resistance. Finally, the ability to modulate the expression of anticancer genes 
may be useful at safer doses for the regression of primary cancers and for the prevention of 
recurrences and metastatic disease. 
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Figure 1. 
Regulated transgene expression within glioblastoma cells from different species using high- 
capacity adenoviral vectors encoding reporter and therapeutic transgenes under the control of 
a third-generation Tet-On system. A, CNS-1 rat glioblastoma cells were infected with high- 
capacity adenoviral vectors encoding β-galactosidase under the control of a third-generation 
Tet-On system. Transgene expression was determined 72 h later by β-galactosidase enzymatic 
activity assay and immunocytochemistry. B, J3T dog glioblastoma cells and IN859 primary 
cultures from human glioma biopsies were infected with high-capacity adenoviral vector 
encoding Flt3L under the control of a Tet-On system for 72 h in the presence or absence of the 
inducer doxycycline (Dox; 1 µg/mL). Transgene expression was determined by ELISA and 
immunocytochemistry. C, COS-7 cells were infected with Ad-muIL4-TRE-muIL-13, which 
expresses muL-4 and muIL-13 under the control of the bidirectional TRE promoter. Transgene 
expression is controlled by a third-generation Tet-On system (see diagram) driven by the 
mCMV promoter in the presence of the inducer Dox. Transgenes were detected in the 
supernatant of COS-7 cells after 72 h by ELISA. 
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Figure 2. 
Immunologic targets for cancer therapeutics. Immature dendritic cells express CCR1, CCR2, 
CCR5, CCR6, and CXCR1 chemokine receptors and migrate in the same direction as the 
concentration gradient of the corresponding cytokines. After phagocytosing tumor antigen, 
dendritic cells then upregulate CCR7 and migrate towards the draining lymph nodes in response 
to MIP3β and SLC. Dendritic cells interact with and stimulate the proliferation of tumor 
antigen-specific T lymphocytes. Activated helper (TH) and cytotoxic (TC) lymphocytes 
migrate into the tumor mass where they initiate tumor regression. Tumor antigens are often 
also expressed by normal cells; therefore, tumor antigen-specific T lymphocytes can also cause 
destruction of normal tissues. Tumor infiltrating regulatory T lymphocytes are essential to 
suppress autoimmune responses but can also down-regulate TH- and TC-induced tumor 
regression. Immune responses can be modulated using gene therapy approaches. However, it 
is important to tightly regulate these functions to reduce the risk of autoimmune diseases 
developing. 
 
  
 
